Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerAggressive B-Cell Lymphoma | January 3, 2025
Fludararabine lymphodepletion is more effective than bendamustine lymphodepletion, but more follow-up is needed to confirm.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Andrew MorenoMeeting News | December 9, 2024
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
Andrew MorenoMeeting News | December 9, 2024
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Julie GouldMeeting News | December 6, 2024
A study stresses psychological support as an essential component of comprehensive cancer care.
Advertisement
Julie GouldMeeting News | December 6, 2024
Good local control over five years using a very low dose approach was possible for potentially curable patients.
Julie GouldMeeting News | December 6, 2024
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
Julie GouldMeeting News | December 6, 2024
Study investigated if high Vulnerable Elders Survey scores were associated with changes in quality of life across age groups.
Greg Nowakowski, MDAggressive B-Cell Lymphoma | December 5, 2024
The panel, moderated by Grzegorz Nowakowski, MD, also assessed the feasibility of a CSF biomarker for this disease.
Greg Nowakowski, MDAggressive B-Cell Lymphoma | December 5, 2024
Transplantation and radiation are prominent topics in this expert panel segment, moderated by Grzegorz Nowakowski, MD.
Greg Nowakowski, MDAggressive B-Cell Lymphoma | December 2, 2024
The panel, moderated by Grzegorz Nowakowski, MD, discussed options like lenalidomide, BTK inhibitors, and clinical trials.
Greg Nowakowski, MDAggressive B-Cell Lymphoma | November 25, 2024
Grzegorz Nowakowski, MD, asks an expert panel about their approaches and special issues they encounter in first-line care.
Stefano Luminari, MDAggressive B-Cell Lymphoma | October 3, 2024
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Melissa BadamoFollicular Lymphoma | August 26, 2024
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | August 23, 2024
Tafasitamab is a humanized, Fc-modified monoclonal antibody that targets the CD19 antigen.
Andrew MorenoAggressive B-Cell Lymphoma | June 6, 2024
A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T.
Lakshmi Nayak, MDAggressive B-Cell Lymphoma | June 4, 2024
These findings concern axi-cel use in relapsed and refractory primary and secondary disease.
Melissa BadamoAggressive B-Cell Lymphoma | June 3, 2024
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Francesco Bertoni, MD, PhDAggressive B-Cell Lymphoma | April 30, 2024
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Advertisement
Advertisement
Editorial Board